Mounjaro

Mounjaro appears in Howard Lutnick: How America Can Hit 6% GDP Growth in 2026 as one of the GLP-1 drugs Howard Lutnick says would become available through Medicaid and Medicare at $149 under the administration’s drug-pricing deals. The source uses Mounjaro with Ozempic as a concrete example inside Most-Favored-Nation Drug Pricing.

The page keeps the claim source-scoped. It does not evaluate clinical use, manufacturer economics, or actual program eligibility; it records how the episode frames the drug as a visible beneficiary of tariff-backed pharmaceutical negotiation.

Connections

• Most-Favored-Nation Drug Pricing - policy frame in which the drug is named.
• GLP-1 Agonists and Ozempic - drug-category and paired product context.
• Eli Lilly - manufacturer context for Mounjaro.
• Medicare, Medicaid, and HHS - public-program branch in the source.